Dr Janette Greenhalgh, Department: Health Data Science

**Abstract** –

Pharmaceutical companies who want to market new drugs into the NHS submit an evidence submission to the National Institute for Health and Care Excellence (NICE). The company submission includes clinical trial evidence and evidence for the cost-effectiveness of the new drug. My team (of clinical reviewers, statisticians, health economic modellers and a clinical expert) goes through the company submission with a fine-tooth comb (and other tools!) and provides an assessment report to NICE. The NICE appraisal committee takes our report into consideration when making recommendations for the new drug. The process is intense, as we have only eight weeks from receiving the company submission to submitting our assessment report to NICE. At the end of the process, our report and the company evidence submission are made available on the NICE website.